Literature DB >> 27109543

What Is the Effect of Metabolic Syndrome without Hypertension on Left Ventricular Hypertrophy?

Mohammad M Al-Daydamony1, Mohammad El-Tahlawi2.   

Abstract

BACKGROUND: Left ventricular hypertrophy (LVH) is an independent risk factor for cardiovascular events. There is a strong association between metabolic syndrome (MetS) and LVH in hypertensive patients. However, the relation between LVH and MetS in the absence of hypertension has not been studied. AIM OF THE WORK: To study the impact of MetS on LV mass in patients without hypertension. SUBJECTS AND METHODS: Fifty MetS patients without hypertension and 50 healthy control subjects were enrolled. Twelve-lead electrocardiography, laboratory testing, and echocardiography were done with assessment of the left ventricular diastolic (LVEDD) and systolic dimensions (LVESD), fraction of shortening (FS), ejection fraction (EF), Doppler-derived mitral valve flow velocity waves (E-wave, A-wave, E/A ratio), left ventricular mass and mass index (LVMI).
RESULTS: There was no significant difference between the two groups regarding LVEDD, LVESD, FS, EF, E-wave velocity, A-wave velocity, or E/A ratio. However, mean posterior wall thickness, IVST, LV mass, LVMI, and incidence of LVH were significantly higher in MetS patients. There was a significant positive correlation between LVMI and blood glucose level (r = 0.528, P < 0.00001), hemoglobin A1c (HbA1c) (r = 0.416, P < 0.0001), triglycerides level (r = 0.535, P < 0.00001), and obesity (r = 0.307, p = 0.0019). There was a significant negative correlation between LVMI and HDL-C level (r = -0.377, P < 0.0001). The same parameters were predictors for LVH in a logistic regression analysis.
CONCLUSION: Even in the absence of hypertension, MetS patients had significantly higher LV wall thickness, LV mass and LVMI, and incidence of LVH than control subjects.
© 2016, Wiley Periodicals, Inc.

Entities:  

Keywords:  diabetes mellitus; dyslipidemia; echocardiography; left ventricular hypertrophy; left ventricular mass; metabolic syndrome

Mesh:

Year:  2016        PMID: 27109543     DOI: 10.1111/echo.13247

Source DB:  PubMed          Journal:  Echocardiography        ISSN: 0742-2822            Impact factor:   1.724


  7 in total

Review 1.  The role of metabolic syndrome in sudden cardiac death risk: Recent evidence and future directions.

Authors:  Amedeo Tirandi; Federico Carbone; Fabrizio Montecucco; Luca Liberale
Journal:  Eur J Clin Invest       Date:  2021-11-08       Impact factor: 5.722

2.  Lipid profile and left ventricular geometry pattern in obese children.

Authors:  Bojko Bjelakovic; Claudia Stefanutti; Vladimir Vukovic; Nebojsa Kavaric; Ljiljana Saranac; Aleksandra Klisic; Stevo Lukic; Sanja Stankovic; Maja Jovic; Sergej Prijic; Marko Bjelakovic; Maciej Banach
Journal:  Lipids Health Dis       Date:  2020-05-26       Impact factor: 3.876

3.  Association of glycemic status and segmental left ventricular wall thickness in subjects without prior cardiovascular disease: a cross-sectional study.

Authors:  Susanne Rospleszcz; Anina Schafnitzel; Wolfgang Koenig; Roberto Lorbeer; Sigrid Auweter; Cornelia Huth; Wolfgang Rathmann; Margit Heier; Birgit Linkohr; Christa Meisinger; Holger Hetterich; Fabian Bamberg; Annette Peters
Journal:  BMC Cardiovasc Disord       Date:  2018-08-09       Impact factor: 2.298

4.  Dysglycemia and increased left ventricle mass in normotensive patients admitted with a first myocardial infarction: prognostic implications of dysglycemia during 14 years of follow-up.

Authors:  Gokulan Pararajasingam; Brian Bridal Løgstrup; Dan Eik Høfsten; Thomas Brøcher Christophersen; Søren Auscher; Jørgen Hangaard; Kenneth Egstrup
Journal:  BMC Cardiovasc Disord       Date:  2019-05-02       Impact factor: 2.298

5.  Hyperhomocysteinemia accompany with metabolic syndrome increase the risk of left ventricular hypertrophy in rural Chinese.

Authors:  Shasha Yu; Yintao Chen; Hongmei Yang; Xiaofan Guo; Liqiang Zheng; Yingxian Sun
Journal:  BMC Cardiovasc Disord       Date:  2020-02-03       Impact factor: 2.298

6.  Alleviation of salt-induced exacerbation of cardiac, renal, and visceral fat pathology in rats with metabolic syndrome by surgical removal of subcutaneous fat.

Authors:  Kiyoshi Aoyama; Yuki Komatsu; Mamoru Yoneda; Shiho Nakano; Sao Ashikawa; Yumeno Kawai; Xixi Cui; Katsuhide Ikeda; Kohzo Nagata
Journal:  Nutr Diabetes       Date:  2020-08-10       Impact factor: 5.097

Review 7.  Nutraceutical, Dietary, and Lifestyle Options for Prevention and Treatment of Ventricular Hypertrophy and Heart Failure.

Authors:  Mark F McCarty
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.